U.S. Patent 5,670,537: Claim Scope, Expiration, Litigation Risk, and Paclitaxel Patent Landscape

U.S. Patent No. 5,670,537 covers a clinical method for treating taxol-sensitive tumors with paclitaxel after hypersensitivity premedication, using a dose of approximately 135-175 mg/m². The core regimen is parenteral administration, generally over about three hours. The patent is a method-of-use patent, not a composition-of-matter or formulation patent.

The patent’s commercial significance was tied to the three-hour paclitaxel infusion regimen used in ovarian and other cancers. Its enforceable term has expired, eliminating current U.S. patent exclusivity based on these claims. The claims remain relevant for historical litigation, claim construction, prior-art analysis, and freedom-to-operate reviews involving older products and past generic launches.

What does U.S. Patent 5,670,537 protect?

The patent protects a treatment protocol combining four principal elements:

A patient with a taxol-sensitive tumor.
Premedication to reduce or eliminate hypersensitivity reactions.
Parenteral administration of taxol, meaning paclitaxel.
A dose of approximately 135-175 mg/m², generally delivered over approximately three hours.

Claims 1, 2, 4, 5 and 8 expressly require administration over about three hours. Claim 3 covers the 135-175 mg/m² dose range for a taxol-sensitive ovarian tumor without expressly reciting the three-hour duration. Claims 6, 7, 9 and 10 narrow the independent claims by specifying premedication categories or ovarian tumors.

Claim group	Patient or tumor	Dose	Infusion period	Premedication	Additional limitation
1	Taxol-sensitive tumor	About 135-175 mg/m²	About 3 hours	Required	Broad treatment claim
2	Taxol-sensitive tumor	About 135 mg/m²	About 3 hours	Required	Narrow dose
3	Taxol-sensitive ovarian tumor	About 135-175 mg/m²	Not expressly required	Required	Ovarian cancer
4	Taxol-sensitive ovarian tumor	About 135 mg/m²	About 3 hours	Required	Narrow dose and tumor
5	Taxol-sensitive tumor	About 135-175 mg/m²	About 3 hours	Required	Reduced hematologic toxicity
6	Taxol-sensitive tumor	Depends on claim 5	About 3 hours	Steroids, antihistamines, H2 antagonists, or combinations	Dependent claim
7	Ovarian tumor	Depends on claims 5 and 6	About 3 hours	Specified categories	Dependent claim
8	Taxol-sensitive tumor	About 135 mg/m²	About 3 hours	Required	Reduced hematologic toxicity
9	Taxol-sensitive tumor	About 135 mg/m²	About 3 hours	Specified categories	Dependent claim
10	Ovarian tumor	About 135 mg/m²	About 3 hours	Specified categories	Dependent claim

The claim set is narrower than a claim to paclitaxel itself. It does not cover every administration of paclitaxel, every dose, every infusion duration, or every cancer treatment involving paclitaxel.

How should the core claim limitations be construed?

What does “taxol” mean in the claims?

In this patent, “taxol” refers to paclitaxel, the taxane anticancer agent. A claim directed to the clinical use of paclitaxel is distinct from a claim directed to docetaxel, cabazitaxel, or another taxane unless the patent specification or prosecution history gives the term an unusually broad construction.

A product containing paclitaxel would satisfy the drug-identity limitation. A product containing docetaxel would not ordinarily satisfy it.

What does “about 135-175 mg/m²” cover?

The word “about” introduces numerical tolerance around the stated range. It does not necessarily convert the claim into an unlimited dose range. A court would examine the specification, prosecution history, scientific convention, and evidence concerning clinically meaningful dose variation.

The literal center of the claimed range is 135-175 mg/m². Doses materially below 135 mg/m² or above 175 mg/m² would present a stronger non-infringement position, although the effect of “about” would depend on the evidence.

Claim 2 and claim 4 are narrower because they specify approximately 135 mg/m². A 175 mg/m² regimen may fall within claims 1, 3, 5 and related claims but not normally within the 135 mg/m²-only claims.

What does “about three hours” cover?

The three-hour limitation is central to claims 1, 2, 4, 5 and 8. A regimen delivered over materially longer periods, such as 24 hours, would create a substantial non-infringement distinction from those claims.

A short variation around three hours may fall within “about three hours.” The analysis would depend on clinical practice and the patent record. A 2.5-hour or 3.5-hour administration is more likely to raise a claim-construction issue than a 24-hour infusion.

Claim 3 is materially broader on infusion duration because it recites the dose range for an ovarian tumor but does not expressly require a three-hour administration.

What does the premedication limitation require?

Every independent claim requires premedication with a medicament that reduces or eliminates hypersensitivity reactions. Claims 6 and 9 identify steroids, antihistamines, H2 receptor antagonists, and combinations of those agents.

A typical paclitaxel premedication protocol includes a corticosteroid, diphenhydramine or another antihistamine, and an H2 antagonist such as ranitidine or famotidine. The FDA Taxol label historically recommended premedication to reduce the frequency and severity of hypersensitivity reactions (FDA, 2011).

Claims 1-5 and 8 use functional language. They do not require a specific listed drug if the administered medicament satisfies the claimed function. Claims 6 and 9 narrow the scope to the recited pharmacological categories.

Which claims are strongest and which are most vulnerable?

Claims 1 and 5 are the principal broad claims. Claim 1 requires the dose, premedication, tumor sensitivity, parenteral route, and three-hour administration. Claim 5 adds the result or association of reduced hematologic toxicity.

Claims 3 and 4 are important ovarian-cancer claims. Claim 3 is potentially broader than the three-hour claims because its text does not specify infusion duration. Claims 6, 7, 9 and 10 are narrower but more specific, which can improve resistance to prior-art attacks while reducing the number of infringing regimens.

The main vulnerabilities are:

Reliance on “about” for dose and infusion duration.
Functional language concerning reduced hypersensitivity reactions and reduced hematologic toxicity.
Potential prior art involving paclitaxel dose-ranging studies.
The requirement that the tumor be taxol-sensitive.
The need to prove the complete treatment protocol, including premedication and administration duration.
The distinction between a physician’s treatment decision and a generic manufacturer’s product conduct.

The reduced-hematologic-toxicity limitation in claims 5 and 8 may operate as a result limitation or as a description of the claimed regimen’s clinical effect. The limitation would not necessarily require a physician to measure blood counts before or after each administration, but proof of the claimed association could become important in litigation.

When did U.S. Patent 5,670,537 expire?

U.S. Patent 5,670,537 issued on September 23, 1997. Its term was based on the applicable U.S. filing and priority history rather than the issue date. The patent’s nominal term ended in December 2013, subject to any patent-term adjustment or other official term calculation recorded by the USPTO.

The patent is expired and does not create a current U.S. patent barrier to a paclitaxel product or regimen. The USPTO Patent Center and the FDA Orange Book are the controlling sources for the official patent and listing records (USPTO, 1997; FDA, 2025).

The patent’s expiration means that a current generic manufacturer does not need to design around the claimed three-hour, premedicated paclitaxel regimen for purposes of avoiding an unexpired claim. Historical infringement exposure remains relevant only to conduct occurring during the enforceable period.

What was the Orange Book status of Patent 5,670,537?

Patent 5,670,537 was associated with the Taxol paclitaxel product and was treated as a method-of-use patent rather than a drug-substance patent. Orange Book-listed method-of-use patents can affect abbreviated new drug application timing through Paragraph IV certifications and the possibility of Hatch-Waxman litigation.

The Orange Book listing did not mean that the patent covered paclitaxel in every form. It identified a particular patented use associated with the approved drug product. A generic applicant could address the listing through:

A Paragraph III certification agreeing to wait until patent expiration.
A Paragraph IV certification asserting that the patent was invalid, unenforceable, or not infringed.
A section viii statement carving out the patented use from the proposed labeling, where legally and factually available.

Because the patent has expired, its Orange Book status no longer creates a prospective delay to ordinary U.S. generic entry. Historical listings remain important for reconstructing approval timing and prior litigation.

Which companies challenged the paclitaxel patent estate?

Bristol-Myers Squibb and its affiliates controlled the U.S. Taxol commercial franchise. Generic paclitaxel development involved multiple pharmaceutical manufacturers, including manufacturers that pursued abbreviated approvals and challenged or designed around patents associated with Taxol.

Public patent records and FDA approval records should be reviewed separately because not every generic applicant that entered the paclitaxel market necessarily challenged Patent 5,670,537 through a litigated Paragraph IV case. A Paragraph IV certification can terminate without a reported merits decision, and a generic can enter after patent expiration or through a labeling carve-out.

The relevant competitive set included generic injectable paclitaxel manufacturers such as Ivax, Mylan, Bedford Laboratories, Mayne Pharma, Sicor, and other ANDA sponsors. The existence of a generic paclitaxel approval does not by itself establish that the sponsor prevailed against every claim of Patent 5,670,537.

What patent litigation affected the three-hour paclitaxel regimen?

The commercial dispute centered on whether generic injectable paclitaxel products could be approved and marketed despite method-of-use patents associated with Taxol. The principal legal issues in this category included:

Whether the generic label induced physicians to practice the patented regimen.
Whether a proposed labeling carve-out adequately removed the patented use.
Whether the patent claims were anticipated or obvious in view of paclitaxel clinical studies.
Whether the dose and infusion-period limitations were met.
Whether premedication was sufficiently linked to the generic product’s intended use.
Whether the relevant conduct occurred before patent expiration.

A generic manufacturer’s exposure was greater where its labeling expressly recommended the patented three-hour, 135-175 mg/m² regimen and hypersensitivity premedication. Exposure was lower where the label omitted the patented indication, used a legally effective section viii carve-out, or marketed the product after expiration.

No current injunction or settlement based solely on Patent 5,670,537 can block U.S. paclitaxel entry because the patent term has ended. Historical settlement terms, if any, would require review of the specific district-court docket and agreement.

How does Patent 5,670,537 compare with formulation and composition patents?

Patent 5,670,537 is weaker as a present-day exclusivity asset because it covers conduct during treatment rather than the paclitaxel molecule or a proprietary delivery platform.

Patent category	Typical protected subject matter	Relevance to Patent 5,670,537
Composition of matter	Paclitaxel molecule or chemical derivatives	Separate from the treatment regimen
Formulation	Solubilizers, excipients, concentrations, stability	May cover a product even when the regimen patent does not
Method of use	Dose, infusion time, patient population, premedication	Direct category of Patent 5,670,537
Manufacturing	Extraction, purification, crystallization, sterile manufacture	Can create technical barriers independent of treatment claims
Drug-device	Infusion systems or delivery devices	Potentially separate from the paclitaxel method
Biologic or nanoparticle delivery	Albumin-bound or other specialized paclitaxel systems	Generally distinct from conventional Taxol injection

Abraxane, the albumin-bound paclitaxel product, illustrates the distinction. Its formulation and delivery technology are different from conventional solvent-based paclitaxel injection. Patent 5,670,537 does not automatically control every use of Abraxane merely because the active ingredient is paclitaxel. Product-specific claims, labeling, dose, infusion duration, and premedication instructions would control the analysis.

What generic launch risks existed during the patent term?

Before expiration, a generic launch could face four principal risks:

Paragraph IV litigation based on the patent listing.
Inducement allegations based on the proposed label.
Direct or contributory infringement theories involving the manufacturer’s instructions and marketing.
Regulatory delay from a 30-month stay following timely infringement litigation.

The strongest non-infringement positions would have involved a label that omitted the patented use, a dose outside the claimed range, an infusion period materially different from three hours, or an administration protocol without the claimed premedication. Those positions could be limited if the proposed label still encouraged physicians to use the patented regimen.

Today, the principal commercial risks are different. They concern manufacturing quality, sterile injectable production, supply continuity, FDA approval, procurement contracts, and separate formulation or delivery patents. Patent 5,670,537 is no longer the principal launch barrier.

How strong is the current patent estate around conventional paclitaxel?

The current U.S. estate for conventional paclitaxel is commercially weaker than it was during the Taxol exclusivity period. The original molecule is long off patent, and the three-hour treatment patent has expired. Remaining value is more likely to reside in:

New formulations.
Nanoparticle or albumin-bound delivery systems.
Combination regimens.
Patient-selection methods.
Biomarker-defined treatment methods.
Manufacturing improvements.
Devices and administration systems.
New indications supported by unexpired method-of-use claims.

A sponsor evaluating a conventional paclitaxel injection therefore faces limited risk from Patent 5,670,537 itself but must conduct a separate freedom-to-operate review for formulation, manufacturing, labeling, and any newer indication patents.

Key Takeaways

U.S. Patent 5,670,537 covers a premedicated paclitaxel treatment regimen.
The principal dose range is approximately 135-175 mg/m².
Several claims require parenteral administration over approximately three hours.
Claim 3 is broader on infusion duration because it does not expressly require three hours.
Claims 6 and 9 identify steroids, antihistamines, H2 antagonists, and combinations as premedication options.
The patent is a method-of-use patent, not a paclitaxel composition or formulation patent.
Its U.S. term expired in December 2013, subject to the official USPTO term record.
It does not currently block generic paclitaxel launch.
Separate formulation, manufacturing, delivery-system, and newer method-of-use patents require independent review.
Historical Paragraph IV and inducement issues remain relevant to reconstructing the Taxol generic-entry disputes.

FAQs About U.S. Patent 5,670,537

Does Patent 5,670,537 cover all Taxol treatments?

No. It covers specified premedicated paclitaxel regimens, principally involving approximately 135-175 mg/m² and, in most claims, an infusion of about three hours.

Does a 24-hour paclitaxel infusion infringe the patent?

The 24-hour regimen would not ordinarily satisfy claims that require administration over about three hours. Claim 3 requires separate analysis because it does not expressly recite an infusion duration.

Does the patent cover docetaxel?

No. The claims are directed to taxol, understood in this context as paclitaxel. Docetaxel is a different taxane.

Can a generic manufacturer market paclitaxel at 175 mg/m² today?

Patent 5,670,537 does not prevent current marketing because its patent term has expired. The manufacturer must still satisfy FDA approval, labeling, manufacturing, and any separate unexpired patent requirements.

Does premedication with only an antihistamine satisfy every claim?

Not necessarily. The broad claims require a medicament that reduces or eliminates hypersensitivity reactions. Claims 6 and 9 expressly permit antihistamines, but infringement also depends on the other limitations, including dose, route, tumor, infusion duration, and any reduced-toxicity limitation.

References

U.S. Patent and Trademark Office. (1997). U.S. Patent No. 5,670,537, “Method for the treatment of taxol-sensitive tumors.”
U.S. Food and Drug Administration. (2011). Taxol (paclitaxel) injection prescribing information. Bristol-Myers Squibb Company.
U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book.
U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application approvals and patent certification requirements.
U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act, Pub. L. No. 98-417.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	152910	⤷ Start Trial
Australia	3216893	⤷ Start Trial
Australia	4207096	⤷ Start Trial
Australia	641894	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 5,670,537

Summary for Patent: 5,670,537